Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Candel Therapeutics, Inc. (CADL : NSDQ)

• Company Description    Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass. Number of Employees: 38

• Price / Volume Information    Yesterday's Closing Price: $6.15 Daily Weekly Monthly 20 Day Moving Average: 949,257 shares Shares Outstanding: 50.10 (millions) Market Capitalization: $308.13 (millions) Beta: -0.91 52 Week High: $14.60 52 Week Low: $3.79 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.74% 10.44% 12 Week 34.57% 13.19% Year To Date -29.15% -33.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 117 KENDRICK STREET SUITE 450 - NEEDHAM,MA 02494 USA ph: 617-916-5445 fax: - tjenkins@candeltx.com http://www.candeltx.com

• General Corporate Information    Officers Paul Peter Tak - President and Chief Executive Officer Paul B. Manning - Chairman Charles Schoch - Interim Chief Financial Officer Edward J. Benz Jr. - Director Chris Martell - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 137404109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 50.10 Most Recent Split Date: (:1) Beta: -0.91 Market Capitalization: $308.13 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.16 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.46 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 37.25% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.06 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 146.43% vs. Previous Quarter: 132.50% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -136.74 12/31/24 - -468.82 ROA 06/30/25 - - 03/31/25 - -63.13 12/31/24 - -118.61 Current Ratio 06/30/25 - - 03/31/25 - 4.64 12/31/24 - 2.77 Quick Ratio 06/30/25 - - 03/31/25 - 4.64 12/31/24 - 2.77 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 1.52 12/31/24 - 1.41 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.04 Debt-to-Capital 06/30/25 - - 03/31/25 - 1.20 12/31/24 - 3.78

Powered by Zacks Investment Research ©